Epigenetic therapy--a new development in pharmacology

Area of Science:

• Pharmacology
• Molecular Biology
• Genetics

Background:

• Epigenetics involves heritable gene expression changes without altering DNA sequence.
• Abnormal DNA methylation and histone modifications are implicated in various diseases.
• Epigenetic alterations contribute to disease pathogenesis, including cancer.

Purpose of the Study:

• To review the emerging field of epigenetic therapy.
• To describe current drug development targeting epigenetic modifications.
• To highlight the therapeutic potential of epigenetic drugs in disease treatment.

Main Methods:

• Review of current pharmacological developments in epigenetic therapy.
• Description of two main drug classes: DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors.
• Summary of findings from drug trials, particularly in oncology.

Main Results:

• DNMT inhibitors reduce DNA methylation, potentially reversing tumor suppressor gene silencing in cancer.
• HDAC inhibitors increase histone acetylation, associated with anticancer effects.
• Both drug classes have demonstrated promising results in clinical trials for cancer treatment.

Conclusions:

• Epigenetic therapy represents a significant advancement in treating diseases linked to epigenetic dysregulation.
• The scope of epigenetic therapy is expected to broaden beyond cancer to other diseases.
• Targeting epigenetic mechanisms offers a promising therapeutic strategy for a wide range of conditions.